Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SOLESENCE, INC. Director's Dealing 2012

Aug 8, 2012

33563_dirs_2012-08-08_f4b8ebde-197e-408f-8f73-23292ebbe575.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOPHASE TECHNOLOGIES CORPORATION (NANX)
CIK: 0000883107
Period of Report: 2012-07-12

Reporting Person: PEARLMAN JERRY K (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-07-12 Common Stock X 10926 $0.33 Acquired 42874 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-07-12 Subscription Rights (right to buy) $0.33 X 31948 Disposed 2012-07-20 Common Stock (10926) Direct
2012-08-07 Stock Option (right to buy) $0.30 A 10000 Acquired 2022-08-07 Common Stock (10000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $3.78 2012-11-25 Common Stock (2000) 2000 Direct
Stock Option (right to buy) $5.07 2013-06-26 Common Stock (2000) 2000 Direct
Stock Option (right to buy) $1.36 2021-01-31 Common Stock (10000) 10000 Direct
Deferred Common Stock $ Common Stock (2000) 20030 Direct
Stock Appreciation Right $0.99 Common Stock (2000) 14000 Direct

Footnotes

F1: The shares were purchased upon exercise of subscription rights issued pro rata to holders of the issuer's common stock (the "Common Stock") as of the close of business on June 13, 2012 (the "Record Date"), to purchase 0.342 shares of Common Stock for each one share of Common Stock owned as of the close of business on the Record Date at a subscription price of $0.33 per full share under the basic subscription privilege of the issuer's rights offering.

F2: The shares of Common Stock were issued to the reporting person shortly after the July 20, 2012 expiration of the rights offering.

F3: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.

F4: Each share of deferred common stock represents a right to receive one share of common stock.

F5: The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.

F6: Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 20,030 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensation Plan.

F7: The stock appreciation right becomes payable upon the reporting person's termination of service as a director of the Company. 2,000 were issued 4/8/2009 at a conversion price of $0.90, 2,000 were issued 7/1/2009 at a conversion price of $1.05, 2,000 were issued 10/1/2009 at a conversion price of $1.18, 2,000 were issued 1/4/2010 at a conversion price of $0.84, 2,000 were issued 4/1/2010 at a conversion price of $1.85, 2,000 were issued 7/1/2010 at a conversion price of $1.10, and 2,000 were issued 10/1/2010 at a conversion price of $0.99.

F8: The reporting person exercised subscription rights issued pro rata to holders of Common Stock as of the close of business on the Record Date, to purchase 0.342 shares of Common Stock for each one share of Common Stock owned as of the close of business on the Record Date at a subscription price of $0.33 per full share under the basic subscription privilege of the issuer's rights offering.